Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02869659 · ClinicalTrials.gov registry record · NA
Valued EpiGenetic Glycemic ImprovEments Through Weight Loss
A NA study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 138
- Enrollment target
NCT02869659 is a NA study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 138 participants.
The verdict
NCT02869659, a NA study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 138 participants
- Enrollment target
Study Summary
This randomized controlled clinical trial will use methylomic and transcriptomic profiling to examine the effects of a weight loss intervention on the cholesterol metabolism gene network in monocytes and adipocytes and investigate the longitudinal relationship between these modifications and glycemic improvements.
Interventions
- BEHAVIORAL Weight Loss Group
- BEHAVIORAL Delayed Weight Loss
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2016-11-01 |
| Est. Completion | 2020-12-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02869659
The ClinicalTrials.gov registry entry for NCT02869659 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Weight Loss Group is the first listed.
NCT02869659 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02869659 about?
NCT02869659 is a clinical study titled "Valued EpiGenetic Glycemic ImprovEments Through Weight Loss". This randomized controlled clinical trial will use methylomic and transcriptomic profiling to examine the effects of a weight loss intervention on the cholesterol metabolism gene network in monocytes and adipocytes and investigate the longitudinal relationship between these modifications and glycemi...
What is the current status of trial NCT02869659?
This trial is currently completed. It is a NA study. The enrollment target is 138 participants. The study started on 2016-11-01. Estimated completion is 2020-12-02.
What interventions are being tested in trial NCT02869659?
The interventions under investigation include: Weight Loss Group (BEHAVIORAL), Delayed Weight Loss (BEHAVIORAL).
Who is sponsoring clinical trial NCT02869659?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.